![Marc E. Uknis](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Marc E.
Uknis served as Vice President-Clinical Development at Achillion Pharmaceuticals, Inc. from 2018 to 2020.
He then worked as Chief Medical Officer at Gemini Therapeutics, Inc. from 2020 to 2021.
Uknis holds an MBA from George Washington University.
Precedenti posizioni note di Marc E. Uknis
Società | Posizione | Fine |
---|---|---|
GEMI THER | Direttore Tecnico/Scientifico/R&S | 11/04/2021 |
ACHILLION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 28/01/2020 |
Formazione di Marc E. Uknis
George Washington University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Achillion Pharmaceuticals, Inc.
![]() Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Gemini Therapeutics, Inc.
![]() Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Marc E. Uknis